Immune to Cancer: The CRI Blog
-
ASCO 2022 Recap: Cancer Immunotherapy Updates
Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought… -
What to Expect in Cancer Immunotherapy in 2021: COVID-19, Biomarkers, and Clinical Trial Design
Dr. Kunle Odunsi shares his thoughts on what lies ahead for the field of cancer immunotherapy.
-
How Immunotherapy for Esophageal Cancer is Making an Impact
Dr. Deirdre Cohen discusses recent advances in immunotherapy for esophageal cancer, including biomarkers, checkpoint inhibitors, cell-based therapies,…
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…
-
ASCO19 Day 2 Update: Biomarkers in Checkpoint Immunotherapy, Targeting Macrophages, and Cellular Immunotherapies
The second day at ASCO19 highlighted biomarkers that may have value in the context of PD-1 checkpoint…
-
AACR19 Recap: Leveraging the Latest Science to Improve Clinical Care
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for…
-
AACR19 Day 4 Update: The Microbiome, Immunotherapy Biomarkers, and New Immune Targets
Day 4 of AACR19 explored the microbiome and its impact on cancer treatment, revealed insights into immunotherapy…
-
IO360 2019 Preview: Collaboration, Investment, Clinical Trials, and Combinations
The fifth annual Immuno-Oncology 360° conference will be held on February 6-8, 2019 in New York City.
-
How Immunotherapy Is Making an Impact in Liver Cancer
We spoke with Bruno Sangro, MD, PhD, about the current treatment landscape for patients with liver cancer,…